scorecardresearch
Add as a preferred source on Google
Saturday, January 3, 2026
TopicSpinal Muscular Atrophy

Topic: Spinal Muscular Atrophy

Roche patent case: Why SC refused to halt Natco’s generic spinal muscular atrophy drug Risdiplam

Roche had approached Delhi High Court, accusing Natco of violating its Indian patent, before going to the Supreme Court with its petition.

India approves Zolgensma, one of world’s costliest drugs. Why it’s sparked hope, but also concern

Zolgensma is the only drug that promises a cure for Spinal Muscular Atrophy, provided it is administered to affected children before the symptoms appear.

New hope for rare disease patients: Rs 900-cr govt project to get high-value drugs at lower rates in works

India has 8.4 to 19 crore rare disease patients, according to health ministry estimates. But current beneficiaries in most cases are kids or those who need relatively less expensive drugs.

On Camera

India’s most consequential decade & chronicling it as part of the dream team of journalism

You’d think the decade of 1985-95 is long over. Not really. The issues that erupted in that decade are still shaping Indian conversations.

India’s urban co-op banks are turning the page—crisis to cautious revival, one metric at a time

With bad loans shrinking & capital buffers stronger, urban co-op banks’ new umbrella body NUCFDC is now prioritising rollout of digital transformation.

Greece looking at TATA’s WhAP infantry combat vehicle for army procurement

If deal goes through, Greece will be 2nd foreign country to procure vehicle. Morocco was first; TATA Group has set up manufacturing unit there with minimum 30 percent indigenous content.

A year-end Mea Culpa in National Interest—The Army-Islam combo doesn’t kill democracy

Many of you might think I got something so wrong in National Interest pieces written this year. I might disagree! But some deserve a Mea Culpa. I’d deal with the most recent this week.